PlainRecalls
FDA Drug Low Class III Terminated

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Reported: October 19, 2016 Initiated: September 13, 2016 #D-0095-2017

Product Description

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Reason for Recall

Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
11,214 vials
Distribution
Nationwide
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.. Recalled by Teva Pharmaceuticals USA. Units affected: 11,214 vials.
Why was this product recalled?
Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 19, 2016. Severity: Low. Recall number: D-0095-2017.